ARISTOTLE-based Stroke Risk (Appraisal of Risk in AF) Calculator
Clinical profile
Enter the clinical characteristics below. This version does not calculate a numerical stroke probability because the equation in the supplied source code could not be verified against a published model.
Clinical context and limitations
The original ARISTOTLE trial evaluated apixaban versus warfarin in patients with atrial fibrillation. A distinct biomarker-based model developed using ARISTOTLE data is the ABC-stroke score (Age, Biomarkers, Clinical history).
The published ABC-stroke model includes age, prior stroke/TIA, NT-proBNP, and high-sensitivity cardiac troponin. It was developed using Cox regression and evaluated for prediction of stroke or systemic embolism. The clinical-only equation in the original Appcardio code is not the published ABC-stroke equation.
Practical use
- Use an established, appropriately validated stroke-risk assessment for routine clinical decision-making.
- Consider the applicable AF guideline, bleeding risk, contraindications, patient preferences, and the clinical context when evaluating anticoagulation.
- Do not interpret the entered profile as a validated risk score or an individualized probability.
References
The ABC (age, biomarkers, clinical history) stroke risk score: a biomarker-based risk score for predicting stroke in atrial fibrillation. European Heart Journal. 2016;37(20):1582–1590.
Performance and Validation of a Novel Biomarker-Based Stroke Risk Score for Atrial Fibrillation. Circulation. 2016;134(22):1697–1707.
Apixaban versus Warfarin in Patients with Atrial Fibrillation. New England Journal of Medicine. 2011;365:981–992.
Clinical notes
Document key findings and keep a structured record for your own reference.
My notes
Review, edit, or remove notes saved in this browser.
Report an issue
Your feedback helps us improve the reliability and usability of this clinical tool.